Evidence map›Paper›PMID 31913340›Full record

ArticleScientific reports2020

Copy number gains of the putative CRKL oncogene in laryngeal squamous cell carcinoma result in strong nuclear expression of the protein and influence cell proliferation and migration.

Magdalena Kostrzewska-Poczekaj, Kinga Bednarek, Malgorzata Jarmuz-Szymczak, Magdalena Bodnar, Violeta Filas, Andrzej Marszalek, Anna Bartochowska, Reidar Grenman, Katarzyna Kiwerska, Krzysztof Szyfter and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Whole-Genome Resequencing Analysis of theInternational journal of molecular sciences · 2024
    Article
  3. Review
  4. Article
  5. Article
  6. Targeting compensatory proliferation signals in oral cancer.Journal of oral biology and craniofacial research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Magdalena Kostrzewska-PoczekajInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland. magkos@man.poznan.pl.
Kinga BednarekInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Malgorzata Jarmuz-SzymczakInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Magdalena BodnarDepartment of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland.
Violeta FilasDepartment of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences & Greater Poland Cancer Center, Poznan, Poland.
Andrzej MarszalekDepartment of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences & Greater Poland Cancer Center, Poznan, Poland.
Anna BartochowskaDepartment of Otolaryngology and Laryngological Oncology, University of Medical Sciences, Poznan, Poland.
Reidar GrenmanDepartment of Otorhinolaryngology, Head and Neck Surgery, Turku University Central Hospital and Turku University, Turku, Finland.
Katarzyna KiwerskaInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Krzysztof SzyfterInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Maciej GiefingInstitute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.
Institute of Human Genetics · PLPoznan University of Medical Sciences · PLPolish Academy of Sciences · PLGreater Poland Cancer Center · PLTurku University Hospital · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laryngeal squamous cell carcinoma is a major medical problem worldwide. Although our understanding of genetic changes and their consequences in laryngeal cancer has opened new therapeutic pathways over the years, the diagnostic as well as treatment options still need to be improved. In our previous study, we identified CRKL (22q11) as a novel putative oncogene overexpressed and amplified in a subset of LSCC tumors and cell lines. Here we analyze to what extent CRKL DNA copy number gains correlate with the higher expression of CRKL protein by performing IHC staining of the respective protein in LSCC cell lines (n = 3) and primary tumors (n = 40). Moreover, the importance of CRKL gene in regard to proliferation and motility of LSCC cells was analyzed with the application of RNA interference (siRNA). Beside the physiological cytoplasmic expression, the analysis of LSCC tumor samples revealed also nuclear expression of CRKL protein in 10/40 (25%) cases, of which three (7.5%), presented moderate or strong nuclear expression. Similarly, we observed a shift towards aberrantly strong nuclear abundance of the CRKL protein in LSCC cell lines with gene copy number amplifications. Moreover, siRNA mediated silencing of CRKL gene in the cell lines showing its overexpression, significantly reduced proliferation (p < 0.01) as well as cell migration (p < 0.05) rates. Altogether, these results show that the aberrantly strong nuclear localization of CRKL is a seldom but recurrent phenomenon in LSCC resulting from the increased DNA copy number and overexpression of the gene. Moreover, functional analyses suggest that proliferation and migration of the tumor cells depend on CRKL expression.

Indexed as

Cell MovementCell ProliferationDNA Copy Number VariationsAdaptor Proteins, Signal TransducingAgedAged, 80 and overBiomarkers, TumorCarcinoma, Squamous CellCell NucleusFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansLaryngeal NeoplasmsMaleMiddle AgedAdaptor Proteins, Signal TransducingBiomarkers, TumorCRKL protein

Identifiers

PMID31913340
PMCPMC6949282
OpenAlexW2998824692

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.